Skip to main content
SpringerLink
Log in
Book cover

Cancer Immunology pp 101–122Cite as

MUC1 mucin as a target for immunotherapy of cancer: Muc1 based immunotherapeutic strategies

  • Chapter

  • 202 Accesses

Part of the book series: Immunology and Medicine Series ((IMME,volume 30))

Abstract

It has been more than a 100 years since the first attempts of cancer immunotherapy were made based on the assumption that tumor cells are recognized as foreign by the immune system. Over the last decade, there has been a considerable increase in our understanding of immune responses against cancer and the antigenic structures on tumor cells that are recognized by the immune system. Tumor antigens have been classified into distinct categories: tissue-specific differentiation antigens, tumor-specific unique antigens and tumor-specific shared antigens. MUC1 belongs to both the first and the last category.. Although MUC1 is expressed on both normal tissue as well as tumors, it has been extensively studied as a tumor antigen in both basic science as well as applied research for a number of exciting reasons. Some of these include its interesting protein structure, extensive glycosylation (which is altered in tumors) increased expression on tumors and changes in cellular distribution upon malignant transformation. In addition, it is very extensively expressed on a variety of human ductal adenocarcinomas. All these facts justify its use as a candidate for tumor-specific immunotherapy. The object of this chapter is to highlight current and past data concerning experimental and clinical immunotherapy of cancer using MUC1 as the target tumor-rejection antigen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen A, Physiology of the gastrointestinal tract, ed. L.R. Johnson. 1981: Raven Press. 627–629.

    Google Scholar 

  2. Gendler SJ, Lancaster CA, Taylorpapadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani E, and Wilson D, Molecular-Cloning and Expression of Human Tumor-Associated Polymorphic Epithelial Mucin. J Biol Chem, 1990; 265: 15286–15293.

    PubMed  CAS  Google Scholar 

  3. Gum JR, Mucin Genes and the Proteins They Encode–Structure, Diversity, and Regulation. Am J Respir Cell Mol Biol, 1992; 7: 557–564.

    PubMed  CAS  Google Scholar 

  4. Neutra MR Forstner JF, Physiology of the Gastrointestinal Tract„ L.R. Johnson, Editor. 1987, Raven Press. p. 975–1009.

    Google Scholar 

  5. Griffiths B, Matthews DJ, West L, Attwood J, Povey S, Swallow DM, Gum JR, Kim YS, Assignment of the Polymorphic Intestinal Mucin Gene (Muc2) to Chromosome-11p15. Ann Hum Genet, 1990; 54: 277–285.

    Article  PubMed  CAS  Google Scholar 

  6. Gum JR, Human mucin glycoproteins: Varied structures predict diverse properties and specific functions. Biochem Soc Trans, 1995; 23: 795–799.

    PubMed  CAS  Google Scholar 

  7. Swallow DM, Gendler S, Griffiths B, Comey G, Taylorpapadimitriou J, and Bramwell ME, The Human Tumor-Associated Epithelial Mucins Are Coded by an Expressed Hypervariable Gene Locus Pum. Nature, 1987; 328: 82–84.

    Article  PubMed  CAS  Google Scholar 

  8. Briand JP, Andrews SP, Cahill E, Conway NA, Young JD, Investigation of the Requirements for 0-Glycosylation by Bovine Sub-Maxillary Gland Udp-N-Acetylgalactosamine - Polypeptide NAcetylgalactosamine Transferase Using Synthetic Peptide- Substrates. J Biol Chem, 1981; 256: 2205 2207.

    Google Scholar 

  9. Hanover JA, Lennarz WJ, Young JD, Synthesis of N- and 0-linked glycopeptides in oviduct membrane preparations. J Biol Chem, 1980; 255: 6713–6716.

    PubMed  CAS  Google Scholar 

  10. Seregni E, Botti C, Massaron S, Lombardo C, Capobianco A, Bogni A, Bombardieri E, Structure, function and gene expression of epithelial mucins. Tumori, 1997; 83: 625–632.

    PubMed  CAS  Google Scholar 

  11. Shankar V, Pichan P, Eddy RL, Tonk V, Nowak N, Sait SNJ, Shows TB, Schultz RE, Gotway G, Elkins RC, Gilmore MS, Sachdev GP, Chromosomal localization of a human mucin gene (MUC8) and cloning of the cDNA corresponding to the carboxy terminus. Am J Respir Cell Mol Biol, 1997; 16: 232–241.

    PubMed  CAS  Google Scholar 

  12. Braga VMM, Pemberton LF, Duhig T, Gendler SJ, Spatial and Temporal Expression of an Epithelial Mucin, Muc-1, During Mouse Development Development, 1992; 115: 427–437.

    CAS  Google Scholar 

  13. Hilkens J, Ligtenberg MJL, Vos HL, Litvinov SV, Cell Membrane-Associated Mucins and Their Adhesion-Modulating Property. Trends Biochem Sci, 1992; 17: 359–363.

    Article  PubMed  CAS  Google Scholar 

  14. Lesuffleur T, Zweibaum A, and Real FX, Mucins in Normal and Neoplastic Human Gastrointestinal Tissues. Crit Rev Oncol Hematol, 1994; 17: 153–180.

    Article  PubMed  CAS  Google Scholar 

  15. Kardon R, Price RE, Julian J, Lagow E, Tseng SCG, Gendler SJ, Carson DD, Bacterial conjunctivitis in Muet null mice. Investigative Ophthalmology & Visual Science, 1999; 40: 1328–1335.

    CAS  Google Scholar 

  16. Gendler SJ Spicer AP, Epithelial Mucin Genes. Annu Rev Physiol, 1995; 57: 607–634.

    Article  Google Scholar 

  17. Lancaster CA, Peat N, Duhig T, Wilson D, Taylorpapadimitriou J, Gendler SJ, Structure and Expression of the Human Polymorphic Epithelial Mucin Gene–an Expressed Vntr Unit. Biochem Biophys Res Commun, 1990; 173: 1019–1029.

    Article  PubMed  CAS  Google Scholar 

  18. Fontenot JD, Mariappan SVS, Catasti P, Domenech N, Finn OJ, Gupta G, Structure of a Tumor-Associated Antigen Containing a Tandemly Repeated Immunodominant Epitope. Journal of Biomolecular Structure & Dynamics, 1995; 13: 245–260.

    Article  CAS  Google Scholar 

  19. Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ, Biophysical Characterization of One-Tandem, 2-Tandem, and 3- Tandem Repeats of Human Mucin (Muc-1) Protein Core. Cancer Res, 1993; 53: 5386–5394.

    PubMed  CAS  Google Scholar 

  20. Miles DW Taylor-Papadimitriou J, Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma Pharmacology & Therapeutics, 1999; 82: 97–106.

    Google Scholar 

  21. Pemberton LF, Rughetti A, TaylorPapadimitriou J, Gendler SJ, The epithelial mucin MUCI contains at least two discrete signals specifying membrane localization in cells. J Biol Chem, 1996; 271: 2332–2340.

    Article  PubMed  CAS  Google Scholar 

  22. Baruch A, Hartmann ML, ZrihanLicht S, Greenstein S, Burstein M, Keydar I, Weiss M, Smorodinsky N, Wreschner DH, Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer, 1997; 71: 741–749.

    Article  PubMed  CAS  Google Scholar 

  23. Stadie TRE, Chai WG, Lawson AM, Byfield PGH, Hanisch FG, Studies on the Order and Site-Specificity of Galnac Transfer to Mucl Tandem Repeats by Udp-Galnac-Polypeptide NAcetylgalactosaminyltransferase from Milk or Mammary-Carcinoma Cells. Eur J Biochem, 1995; 229: 140–147.

    Article  PubMed  CAS  Google Scholar 

  24. Nishimori I, Perini F, Mountjoy KP, Sanderson SD, Johnson N, Cerny RL, Gross ML, Fontenot JD, Hollingsworth MA, N-Acetylgalactosamine Glycosylation of Mucl Tandem Repeat Peptides by Pancreatic Tumor-Cell Extracts. Cancer Res, 1994; 54: 3738–3744.

    PubMed  CAS  Google Scholar 

  25. Nishimori I, Johnson NR, Sanderson SD, Perini F, Mountjoy K, Cerny RL, Gross ML, Hollingsworth MA, Influence of Acceptor Substrate Primary Amino-Acid-Sequence on the Activity of Human Udp-N-Acetylgalactosamine-Polypeptide N- Acetylgalactosaminyltransferase–Studies with the Mud Tandem Repeat J Biol Chem, 1994; 269: 16123–16130.

    CAS  Google Scholar 

  26. Muller S, Goletz S, Packer N, Gooley A, Lawson AM, Hanisch FG, Localization of Oglycosylation sites on glycopeptide fragments from lactation-associated MUC!–All putative sites within the tandem repeat are glycosylation targets in vivo. J Biol Chem, 1997; 272: 24780–24793.

    Article  PubMed  CAS  Google Scholar 

  27. Xing PX, Prenzoska J, McKenzie IFC, Epitope Mapping of Anti-Breast and Antiovarian Mucin Monoclonal-Antibodies. Mol Immunol, 1992; 29: 641–650.

    Article  PubMed  CAS  Google Scholar 

  28. Litvinov SV and Hilkens J, The Epithelial Sialomucin, Episialin, Is Sialylated During Recycling. J Biol Chem, 1993; 268: 21364–21371.

    PubMed  CAS  Google Scholar 

  29. Pimental RA, Julian J, Gendler SJ, Carson DD, Synthesis and intracellular trafficking of Muc-1 and mucins by polarized mouse uterine epithelial cells. J Biol Chem, 1996; 271: 28128–28137.

    Article  PubMed  CAS  Google Scholar 

  30. Hanisch FG, Stadie TRE, Deutzmann F, and PeterKatalinic J, MUCI glycoforms in breast cancer–Cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. Eur J Biochem, 1996; 236: 318–327.

    Article  PubMed  CAS  Google Scholar 

  31. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylorpapadimitriou J, Mechanisms Underlying Aberrant Glycosylation of Mucl Mucin in Breast-Cancer Cells. Eur J Biochem, 1995; 233: 607–617.

    Article  PubMed  CAS  Google Scholar 

  32. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ, Humoral Immunity against a Tandem Repeat Epitope of Human Mucin Muc-1 in Sera from Breast, Pancreatic, and Colon-Cancer Patients. Cancer Res, 1994; 54: 2856–2860.

    PubMed  CAS  Google Scholar 

  33. Xing PX, Tjandra JJ, Stacker SA, Teh JG, Thompson CH, McLaughlin PJ, McKenzie IFC, Monoclonal-Antibodies Reactive with Mucin Expressed in Breast- Cancer. Immunol Cell Biol, 1989; 67: 183–195.

    Article  PubMed  Google Scholar 

  34. Petrarca C, Casalino B, von Mensdorff-Pouilly S, Rughetti A, Rahimi H, Scambia G, Hilgers J, Frati L, Nuti M, Isolation of MUCI-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunology Immunotherapy, 1999; 47: 272–277.

    Article  CAS  Google Scholar 

  35. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA, Antibodies reactive with the protein core of MUC 1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunology Immunotherapy, 1998; 46: 245–252.

    Article  CAS  Google Scholar 

  36. Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M, Human B-Cell Immune-Response to the Polymorphic Epithelial Mucin. Cancer Res, 1993; 53: 2457–2459.

    PubMed  CAS  Google Scholar 

  37. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, Kenemans P, Vankamp GJ, Verstraeten AA, and Hilgers J, Polymorphic Epithelial Mucin (Muc-1)-Containing Circulating Immune-Complexes in Carcinoma Patients. Br J Cancer, 1995; 72: 934–938.

    Article  PubMed  CAS  Google Scholar 

  38. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, Litvinov SV, vanKamp GJ, Meijer S, Vermorken J, and Hilgers J, Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer, 1996; 32A: 1325–1331.

    Article  Google Scholar 

  39. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, and DeNardo GL, Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res, 1997; 17: 1735 1744.

    Google Scholar 

  40. DeNardo SJ, Ogrady LF, Richman CM, Goldstein DS, Odonnell RT, DeNardo DA, Kroger LA, Lambom KR, Hellstrom KE, Hellstrom I, and DeNardo GL, Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res, 1997; 17: 1745–1751.

    PubMed  CAS  Google Scholar 

  41. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JSW, Mason P, Lambert HE, and Epenetos AA, Adjuvant Therapy of Ovarian-Cancer with Radioactive Monoclonal- Antibody. Br J Cancer, 1993; 68: 403–406.

    Article  PubMed  CAS  Google Scholar 

  42. Katayose Y, Kudo T, Suzuki M, Shinoda M, Saijyo S, Sakurai N, Saeki H, Fukuhara K, Imai K, and Matsuno S, MUC 1-specific targeting immunotherapy with bispecific antibodies: Inhibition of xenografted human bile duct carcinoma growth. Cancer Res, 1996; 56: 4205–4212.

    PubMed  CAS  Google Scholar 

  43. Jerome KR, Bamd DL, Bendt KM, Boyer CM, Taylorpapadimitriou J, McKenzie IFC, Bast RC, and Finn OJ, Cytotoxic Lymphocytes-T Derived from Patients with Breast Adenocarcinoma Recognize an Epitope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant-Cells. Cancer Res, 1991; 51: 2908–2916.

    PubMed  CAS  Google Scholar 

  44. Jerome KR, Domenech N, and Finn OJ, Tumor-Specific Cytotoxic T-Cell Clones from Patients with Breast and Pancreatic Adenocarcinoma Recognize Ebv-Immortalized B-Cells Transfected with Polymorphic Epithelial Mucin Complementary-DNA J Immunol, 1993; 151: 1654–1662.

    CAS  Google Scholar 

  45. Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC, and Finn OJ, Intercellular and intracellular events following the MHC- unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol, 1998; 160: 3111–3120.

    PubMed  CAS  Google Scholar 

  46. Domenech N, Henderson RA, and Finn OJ, Identification of an Hla-Al 1-Restricted Epitope from the Tandem Repeat Domain of the Epithelial Tumor-Antigen Mucin. J Immunol, 1995; 155: 4766–4774.

    PubMed  CAS  Google Scholar 

  47. Hiltbold EM, Alter MD, Ciborowski P, and Finn OJ, Presentation of MUCI tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol, 1999; 194: 143–149.

    Article  PubMed  CAS  Google Scholar 

  48. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, and Brugger W, Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood, 1999; 93: 4309–4317.

    PubMed  CAS  Google Scholar 

  49. Hiltbold EM, Ciborowski P, and Finn OJ, Naturally processed class II epitope from the tumor antigen MUCI primes human CD4(+) T cells. Cancer Res, 1998; 58: 5066–5070.

    PubMed  CAS  Google Scholar 

  50. Peat N, Gendler SJ, Lalani EN, Duhig T, and Taylorpapadimitriou 1, Tissue-Specific Expression of a Human Polymorphic Epithelial Mucin (Mucl) in Transgenic Mice. Cancer Res, 1992; 52: 1954–1960.

    PubMed  CAS  Google Scholar 

  51. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, and Gendler SJ, Tolerance and immunity to MUCI in a human MUC1 transgenic murine model. Cancer Res, 1998; 58: 315–321.

    PubMed  CAS  Google Scholar 

  52. Gong JL, Chen DS, Kashiwaba M, Li YQ, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, and Kufe D, Reversal of tolerance to human MUCI antigen in MUCI transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A, 1998; 95: 6279–6283.

    Article  PubMed  CAS  Google Scholar 

  53. Gong JL, Chen DS, Kashiwaba M, and Kufe D, Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med, 1997; 3: 558–561.

    Article  PubMed  CAS  Google Scholar 

  54. Tempero RM, Rowse GJ, Gendler SJ, and Hollingsworth MA, Passively transferred anti-MUCI antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Int J Cancer, 1999; 80: 595–599.

    Article  PubMed  CAS  Google Scholar 

  55. Tempero RM, VanLith ML, Morikane K, Rowse GJ, Gendler SJ, and Hollingsworth MA, CD4(+) lymphocytes provide MUCI-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUCI transgenic mice. J Immunol, 1998; 161: 5500–5506.

    PubMed  CAS  Google Scholar 

  56. Ding L, Lalani E, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PYS, Taylorpapadimitriou J, and Longenecker BM, Immunogenicity of Synthetic Peptides Related to the Core Peptide Sequence Encoded by the Human Mucl Mucin Gene–Effect of Immunization on the Growth of Murine Mammary Adenocarcinoma Cells Transfected with the Human Mucl Gene. Cancer Immunology Immunotherapy, 1993; 36: 9–17.

    Article  CAS  Google Scholar 

  57. Reddish MA, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, and Longenecker BM, Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUCI peptide. Int J Cancer, 1998; 76: 817–823.

    Article  PubMed  CAS  Google Scholar 

  58. Apostolopoulos V, Pietersz GA, Xing PX, Lees CJ, Michael M, Bishop J, and McKenzie IFC, The Immunogenicity of Mucl Peptides and Fusion Protein. Cancer Lett, 1995; 90: 21–26.

    Article  PubMed  CAS  Google Scholar 

  59. Apostolopoulos V, Pietersz GA, and McKenzie IFC, Cell-mediated immune responses to MUCI fusion protein coupled to mannan. Vaccine, 1996; 14: 930–938.

    Article  PubMed  CAS  Google Scholar 

  60. Apostolopoulos V, Popovski V, and McKenzie IFC, Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC I -Mannan fusion protein (M-FP). J Immunother, 1998; 21: 109–113.

    Article  PubMed  CAS  Google Scholar 

  61. Vaughan HA, Ho DWM, Karanikas VA, Ong CS, Hwang LA, Pearson JM, McKenzie IFC, and Pietersz GA, Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUCI conjugates. Vaccine, 1999; 17: 2740–2752.

    Article  PubMed  CAS  Google Scholar 

  62. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, and McKenzie IFC, Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest, 1997; 100: 2783–2792.

    Article  PubMed  CAS  Google Scholar 

  63. Goydos JS, Elder E, Whiteside TL, Finn OJ, and Lotze MT, A phase I trial of a synthetic mucin peptide vaccine induction of specific immune reactivity in patients with adenocarcinoma J Surg Res, 1996; 63: 298–304.

    CAS  Google Scholar 

  64. Barratt-Boyes SM, Vlad A, and Finn OJ, Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res, 1999; 5: 1918–1924.

    PubMed  CAS  Google Scholar 

  65. Newman KD, Sosnowski DL, Kwon GS, and Samuel J, Delivery of MUC1 mucin peptide by poly(d,llactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci, 1998; 87: 1421–1427.

    Article  PubMed  CAS  Google Scholar 

  66. Samuel J, Budzynski WA, Reddish MA, Ding L, Zimmermann GL, Krantz MJ, Koganty RR, and Longenecker BM, Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer, 1998; 75: 295–302.

    Article  PubMed  CAS  Google Scholar 

  67. GalliStampino L, Meinjohanns E, Frische K, Meldal M, Jensen T, Werdelin O, and Mouritsen S, T-cell recognition of tumor-associated carbohydrates: The nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res, 1997; 57: 3214–3222.

    CAS  Google Scholar 

  68. Springer GF, T and Tn, general carcinoma autoantigens. Science, 1984; 224: 1198–1206.

    Article  PubMed  CAS  Google Scholar 

  69. Kieber-Emmons T, Luo P, Qiu JP, Chang TY, O IS, Blaszczyk-Thurin M, and Steplewski Z, Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol, 1999; 17: 660–665.

    Article  PubMed  CAS  Google Scholar 

  70. Lo-Man R, Bay S, Vichier-Guerre S, Deriaud E, Cantacuzene D, and Leclerc C, A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. Cancer Res, 1999; 59: 1520–1524.

    PubMed  CAS  Google Scholar 

  71. Henningsson CM, Selvaraj S, Maclean GD, Suresh MR, Noujaim AA, and Longenecker BM, T-Cell Recognition of a Tumor-Associated Glycoprotein and Its Synthetic Carbohydrate Epitopes–Stimulation of Anticancer T- Cell Immunity Invivo. Cancer Immunology Immunotherapy, 1987; 25: 231–241.

    Article  CAS  Google Scholar 

  72. Longenecker BM, Reddish M, Koganty R, and Maclean GD, Immune-Responses of Mice and Human Breast-Cancer Patients Following Immunization with Synthetic Sialyl-Tn Conjugated to Klh Plus Detox Adjuvant Ann N Y Acad Sci, 1993; 690: 276–291.

    CAS  Google Scholar 

  73. MacLean GD, Miles DW, Rubens RD, Reddish MA, and Longenecker BM, Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother, 1996; 19: 309–316.

    Article  CAS  Google Scholar 

  74. MacLean GD, Reddish MA, Koganty RR, and Longenecker BM, Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother, 1996; 19: 59–68.

    Article  CAS  Google Scholar 

  75. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, and Longenecker BM, Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with theratope STn-KLH cancer vaccine. J Immunother, 1999; 22: 54–66.

    Article  PubMed  CAS  Google Scholar 

  76. Acres RB, Hareuveni M, Balloul JM, and Kieny MP, Vaccinia Virus Mucl Immunization of Mice–Immune-Response and Protection against the Growth of Murine Tumors Bearing the Mucl Antigen. J Immunother, 1993; 14: 136–143.

    Article  CAS  Google Scholar 

  77. Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, and Kantor JA, Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murne T-cell costimulatory molecule B7. J Immunother, 1997; 20: 38–47.

    Article  PubMed  CAS  Google Scholar 

  78. Balloul JM, Acres RB, Geist M, Dott K, Stefani L, Schmitt D, Drillien R, Spehner D, McKenzie I, Xing PX, and Kieny MP, Recombinant Muc-1 Vaccinia Virus–a Potential Vector for Immunotherapy of Breast-Cancer. Cell Mol Biol, 1994; 40: 49–59.

    PubMed  CAS  Google Scholar 

  79. Scholl S, Acres RB, Schatz C, Kieny MP, Balloul JM, Vincent-Salomon A, Deneux L, Tartour E, Fridman H, and Pouillart P, The polymorphic epithelial mucin (MUC1): a phase I clinical trial testing the tolerance and immunogenicity of a vaccina virus-MUC1–IL2 construct in breast cancer. Breast Cancer Res Treat, 1997; 46: 67.

    Google Scholar 

  80. Graham RA, Burchell JM, Beverley P, and TaylorPapadimitriou J, Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer, 1996; 65: 664–670.

    Article  PubMed  CAS  Google Scholar 

  81. Chen LP, Linsley PS, and Hellstrom KE, Costimulation of T-Cells for Tumor-Immunity. Immunol Today, 1993; 14: 483–486.

    Article  PubMed  CAS  Google Scholar 

  82. Pecher G and Finn OJ, Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA- transfected Epstein-Barr virus immortalized autologous B cells. Proc Natl Acad Sci U S A, 1996; 93: 1699–1704.

    Article  PubMed  CAS  Google Scholar 

  83. Barratt-Boyes SM, Kao H, and Finn OJ, Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. J Immunother, 1998; 21: 142–148.

    Article  PubMed  CAS  Google Scholar 

  84. Graham R, Stewart L, Peat N, Beverley P, and Taylor-Papadimitriou J, MUC 1-based immunogens for tumour therapy:development of murine model systems. Tumor Target, 1995; 1: 211–221.

    CAS  Google Scholar 

  85. Henderson RA, Konitsky WM, Barratt-Boyes SM, Soares M, Robbins PD, and Finn OJ, Retroviral expression of MUC-1 human tumor antigen with intact repeat structure and capacity to elicit immunity in vivo. J Immunother, 1998; 21: 247–256.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. J Finn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Immunology, Nottingham University Queen’s Medical Centre, Nottingham, UK

    R. Adrian Robins

  2. Department of Life Sciences, The Nottingham Trent University, Nottingham, UK

    Robert C. Rees

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Soares, M., Finn, O.J. (2001). MUC1 mucin as a target for immunotherapy of cancer: Muc1 based immunotherapeutic strategies. In: Robins, R.A., Rees, R.C. (eds) Cancer Immunology. Immunology and Medicine Series, vol 30. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-0963-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-0963-7_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-5714-3

  • Online ISBN: 978-94-017-0963-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation